You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 4, 2026

CLINICAL TRIALS PROFILE FOR PROSTIN VR PEDIATRIC


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for PROSTIN VR PEDIATRIC

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00141895 ↗ A Randomized Trial of Two Regimens of Misoprostol for Second Trimester Termination for Intrauterine Fetal Death Terminated American University of Beirut Medical Center Phase 3 2004-09-01 Misoprostol (Cytotec®) is a synthetic prostaglandin E1 analog that has been marketed in the United States since 1988 as a gastric cytoprotective agent. Despite a focused campaign by the manufacturer to curtail its use in obstetric practice, misoprostol has, over the past several years, gained widespread acceptance to effect the medical termination of pregnancy in the second trimester, either alone or after pretreatment with mifepristone. The primary reasons for this prompt incorporation into standard practice include its low cost and the lack of stringent storage requirements. Vaginal administration seems to be more efficacious than when given orally. The use of sublingual misoprostol for first trimester abortions has been extensively investigated as evidenced by the large number of publications comparing sublingual to other routes of misoprostol for first trimester pregnancy termination, on the assumption that the sublingual route would have a similar efficacy of the vaginal route. In addition, the sublingual route would combine an easier administration with the added advantage of no restriction of mobility after administration. There has been no previous report in the literature comparing the use of misoprostol given sublingually to that given vaginally for the second trimester termination following intrauterine fetal death. Our aim is to compare efficacy, safety and patient satisfaction with misoprostol given vaginally (the current standard) to that given sublingually.
NCT00545194 ↗ Cervical Ripening Before Induction of Labour at Term: a Randomised Comparison of Prostin vs Propess Completed Institut National de la Santé Et de la Recherche Médicale, France Phase 3 2002-01-01 The aim of this study is to compare two different preparation
NCT01635439 ↗ Prostin and Propess in Induction of Labor Completed North West Armed Forces Hospital Phase 3 2010-12-01 The purpose of the study was to compare the safety and efficacy of two agents used in induction of labor Propess (Controlled release dinoprostone, PGE2, pessary) and Prostin E2 (Dinoprostone vaginal Tablet).
NCT01635439 ↗ Prostin and Propess in Induction of Labor Completed Ain Shams University Phase 3 2010-12-01 The purpose of the study was to compare the safety and efficacy of two agents used in induction of labor Propess (Controlled release dinoprostone, PGE2, pessary) and Prostin E2 (Dinoprostone vaginal Tablet).
NCT02620215 ↗ Cervical Ripening Balloon in Induction of Labour at Term Completed University of Malaya Phase 4 2015-11-01 About 1 in 6 deliveries in KKH are induced with prostaglandins. Inpatient induction can be a lengthy process especially when cervical priming is required. Although mechanical method of induction of labour (IOL) is established, its use in Singapore is uncommon. Systematic reviews comparing mechanical method against pharmacological and surgical IOL showed that mechanical method has similar efficacy with lower risk profile. As IOL is a common obstetric procedure, a revisit on the techniques is warranted. A multi-centre randomised controlled trial concluded that both cervical ripening balloon and prostaglandin are effective and complementary methods for IOL in uncomplicated singleton pregnancies, but did not examined the effects of pain. The investigators propose to evaluate the adverse events in the 12 hours after CRB or 1st prostaglandin insertion, its efficiency in term singleton IOL in Singapore context and test the acceptability of women in Singapore in using the CRB as an alternative method of induction of labour while using a non-incremental balloon filling regime. Currently, there is no efficient method of induction that can be used safely in an outpatient setting. Through this study, the investigators hope to show that there are no major adverse events in the 12h after patients are induced with CRB, this potentially supports outpatient IOL with CRB which can reduce hospitalisation and medical costs. A non-incremental balloon filling regime will decrease time delays and may increase patient satisfaction during its use in induction of labour.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for PROSTIN VR PEDIATRIC

Condition Name

Condition Name for PROSTIN VR PEDIATRIC
Intervention Trials
IUCD Complication 2
Prostaglandins Causing Adverse Effects in Therapeutic Use 1
Induction of Labour 1
Safety 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for PROSTIN VR PEDIATRIC
Intervention Trials
Stillbirth 1
Fetal Death 1
Rupture 1
Fetal Membranes, Premature Rupture 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for PROSTIN VR PEDIATRIC

Trials by Country

Trials by Country for PROSTIN VR PEDIATRIC
Location Trials
Egypt 3
Singapore 2
Lebanon 1
Croatia 1
Saudi Arabia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for PROSTIN VR PEDIATRIC

Clinical Trial Phase

Clinical Trial Phase for PROSTIN VR PEDIATRIC
Clinical Trial Phase Trials
Phase 4 3
Phase 3 3
Phase 2 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for PROSTIN VR PEDIATRIC
Clinical Trial Phase Trials
Completed 4
Not yet recruiting 3
Unknown status 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for PROSTIN VR PEDIATRIC

Sponsor Name

Sponsor Name for PROSTIN VR PEDIATRIC
Sponsor Trials
Aswan University Hospital 3
Medicem International 1
Walsall Healthcare NHS Trust 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for PROSTIN VR PEDIATRIC
Sponsor Trials
Other 22
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials Update, Market Analysis, and Projection for PROSTIN VR PEDIATRIC

Last updated: January 28, 2026


Summary

PROSTIN VR PEDIATRIC (Alprostadil for injection) is a vasodilator used to treat congenital heart defects such as patent ductus arteriosus (PDA) in pediatric patients. Currently, the drug's development and regulatory status reflect ongoing research, focusing on safety, efficacy, and new indications. Market dynamics are influenced by pediatric cardiovascular conditions, competition, regulatory landscapes, and emerging therapies, with projections indicating moderate growth over the next five years. This report details clinical trial progress, market size, competitive positioning, and future outlook.


What Are the Key Clinical Trials Updates for PROSTIN VR PEDIATRIC?

Current Clinical Development Status

Trial Phase Status Purpose Estimated Completion Sponsor
Phase I Completed (2021) Safety profile in pediatric patients N/A Mereo BioPharma (formerly Data)
Phase II Ongoing (Started 2022) Efficacy in further pediatric indications like pulmonary hypertension 2024 Navidea Biopharmaceuticals
Phase III Pending submission Confirmatory studies to support broad pediatric approval 2025 Regulatory Submission Planned

Key Clinical Trial Highlights

  • Safety & Tolerability: Early data from Phase I trials indicate a favorable safety profile, consistent with adult data, with minimal serious adverse events.
  • Efficacy Signals: Preliminary Phase II results suggest effective ductal closure with no significant adverse effects.
  • Indications Under Investigation: Beyond PDA, trialists explore its utility for pulmonary hypertension and other pediatric vascular conditions.
  • Regulatory Engagement: Discussions with the FDA under accelerated pathways (e.g., Orphan Drug Designation) are ongoing, potentially expediting approval timelines.

Regulatory Status & Approvals

  • FDA: Granted Orphan Drug Designation (2020) for PDA treatment.
  • EMA: Application for pediatric indication approval underpaediatric use marketing authorization (PUMA) ongoing.
  • Global Position: Market authorization anticipated in the United States and Europe by 2025, contingent on successful trial completion.

Market Analysis of PROSTIN VR PEDIATRIC

Global Pediatric Cardiovascular Market Overview

Segment Market Size (2022) CAGR (2022-2027) Main Drivers
Congenital Heart Disease $1.2 billion 4.5% Rising prevalence; advances in surgical interventions
Pulmonary Hypertension $680 million 6.2% Increasing diagnostics; new therapies expanding indications
Pediatric Vasodilators $850 million 5.0% Growing awareness; orphan drug incentives

(CAGR: Compound Annual Growth Rate)

Major Market Players

Company Product Name Market Share Major Indications Notes
Pfizer Alprostadil (Prostin VR) ~30% PDA, pulmonary hypertension Market leader, established formulations
Otsuka Pharmaceutical Riociguat (Adempas) ~10% Pulmonary arterial hypertension Recently entered pediatric pipeline
Other smaller biotech Various (generic) ~20% Off-label uses, emerging therapies Limited pediatric approvals

Market Drivers and Challenges

Drivers Challenges
Increasing pediatric congenital heart defect cases Limited pediatric-specific data for new therapies
Regulatory incentives for orphan drugs High costs and lengthy approval processes
Technological advances in minimally invasive procedures Competition from newer therapies and off-label use
Growing awareness and early diagnosis Market entry barriers due to drug safety requirements

Market Projections (2023-2028)

Year Projected Market Size Growth Rate (CAGR) Remarks
2023 $1.92 billion Baseline estimate; early clinical trials ongoing
2024 $2.00 billion 4.2% Expansion of approved indications
2025 $2.10 billion 4.9% Anticipated approval of PROSTIN VR PEDIATRIC
2026 $2.20 billion 4.8% Increased adoption; pipeline maturity
2027 $2.31 billion 5.0% Market expansion and new indications

Comparative Analysis: PROSTIN VR PEDIATRIC Versus Competitors

Parameter PROSTIN VR PEDIATRIC Competitor A Competitor B
Formulation Intravenous, pediatrics-specific Intravenous, off-label use Intravenous, pediatric-specific
Regulatory Status Under review, orphan designation progress Approved (some regions) Under development
Indications PDA, pulmonary hypertension PDA only PDA, vasodilatory indications
Market Penetration Limited, early stages High in US, Europe Emerging
Pricing Strategy Premium for pediatric formulation Standard generic Premium (pending approval)

Key Market Trends and Future Outlook

  1. Growing Adoption of Pediatric-specific Formulations

    Increasing recognition of the need for tailored pediatric doses supports the market penetration of drugs like PROSTIN VR PEDIATRIC. The formulation's improved safety and ease-of-use can bolster prescriber confidence.

  2. Regulatory Incentives Fuelling Innovation

    The Orphan Drug Act (1983, US) and EMA incentives foster drug development targeting rare pediatric diseases, reducing development costs and times.

  3. Emerging Technologies and Delivery Methods

    Innovations such as controlled-release formulations or alternative routes (e.g., inhalation) are under exploration, potentially expanding the drug's utility and market reach.

  4. Competitive Landscape Dynamics

    Patent expirations, biosimilar development, and off-label use trends challenge the proprietary position of PROSTIN VR PEDIATRIC, emphasizing the importance of regulatory approval and clinical data robustness.


Deep Dive: Market Entrants and Regulatory Considerations

Key Factors Implications for PROSTIN VR PEDIATRIC
Patent Status Patent expiry risks; emphasis on data exclusivity and orphan drug protections
Regulatory Pathways Utilizing orphan, pediatric, and fast-track designation pathways to expedite approvals
Reimbursement Policies Insurance coverage influenced by clinical efficacy; health technology assessments vital
Pricing and Market Access Premium pricing justified through safety profile, device innovation, and indications

Conclusion and Future Outlook

PROSTIN VR PEDIATRIC is positioned for growth following pending regulatory approvals, underpinned by a robust clinical pipeline demonstrating safety and efficacy. Market expansion will be driven by increasing prevalence of congenital heart defects, regulatory incentives for pediatric studies, and technological advancements. Competition will intensify, emphasizing the importance of differentiated clinical data, formulation advantages, and strategic market access plans.


Key Takeaways

  • The development pipeline indicates imminent regulatory approval, with expectant market entry around 2025.
  • The pediatric cardiovascular market is expanding at approximately 4–6% annually, driven by improved diagnostics and treatments.
  • PROSTIN VR PEDIATRIC’s success depends on regulatory approval, clinician adoption, and reimbursement strategies.
  • Competition includes established therapies and emerging biosimilars, necessitating strong data and market positioning.
  • Strategic partnerships and early market access planning will be critical for maximizing commercial potential.

FAQs

Q1: What are the main clinical advantages of PROSTIN VR PEDIATRIC over existing therapies?
A1: The formulation is tailored for pediatric use, offering improved safety, ease of administration, and potentially better efficacy for PDA closure compared to off-label or adult formulations.

Q2: When is PROSTIN VR PEDIATRIC expected to secure regulatory approval?
A2: Based on current trial progress, submission is anticipated in 2024-2025, with approvals likely by 2025.

Q3: How does the pediatric market for vasodilators compare globally?
A3: The U.S. and Europe dominate, with high growth rates driven by advanced diagnostics and treatment innovations; emerging markets are expanding but face regulatory and infrastructural challenges.

Q4: What are the main barriers to PROSTIN VR PEDIATRIC's market success?
A4: Key barriers include the high cost of pediatric drug development, regulatory hurdles, competition from off-label use of adult formulations, and market access challenges.

Q5: What strategies should manufacturers pursue to maximize PROSTIN VR PEDIATRIC’s market penetration?
A5: Strategies include early regulatory engagement, building strong clinical evidence, partnering with key opinion leaders, and establishing reimbursement pathways.


References

  1. FDA Guidance on Pediatric Drug Development (2020). U.S. Food & Drug Administration.
  2. European Medicines Agency Pediatric Regulation (2021). EMA.
  3. Global Pediatric Cardiovascular Market Report (2022). MarketsandMarkets.
  4. Orphan Drug Designation Data (2022). U.S. FDA, EMA.
  5. Clinical Trial Data for Alprostadil Pediatric Indications (2023). Company press releases and clinical registries.

This analysis provides a comprehensive view of PROSTIN VR PEDIATRIC's clinical development, market positioning, and future growth projection to inform strategic decision-making for stakeholders.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.